The FDA Has Granted Fast Track Designation To Kymera Therapeutics' KT-333 For The Treatment Of Relapsed/Refractory Cutaneous T-Cell Lymphoma And Peripheral T-Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted Fast Track designation to Kymera Therapeutics' KT-333 for the treatment of relapsed/refractory cutaneous T-cell lymphoma and peripheral T-cell lymphoma.
September 18, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kymera Therapeutics' KT-333 has received Fast Track designation from the FDA, potentially accelerating its development and review process.
The FDA's Fast Track designation is a significant regulatory milestone that can accelerate the development and review process of a drug. This could potentially lead to earlier approval and market entry, which would be beneficial for Kymera Therapeutics. Therefore, this news is likely to have a positive impact on KYMR's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100